A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients.

ABSTRACT:

Purpose

To characterize the population pharmacokinetics of bevacizumab, its binding properties to VEGF165 and the effect of demographic data and VEGF-A polymorphisms on the interplay between bevacizumab serum pharmacokinetics and VEGF165 serum concentrations in patients with colorectal cancer stage IV.

Methods

Bevacizumab and VEGF165 data were collected from 19 adult patients with metastatic colorectal cancer enrolled in an observational clinical study. Bevacizumab was administered with one of the following combinations: 5-FU/Leucovorin/Irinotecan, 5-FU/Leucovorin/Oxaliplatin, Capecitabine/Irinotecan at doses ranging from 5 to 10 mg/kg every 2 or 3 weeks. Data analysis was performed using nonlinear mixed-effects modeling implemented in NONMEM 7.3.

Results

A target-med

SUBMITTER: Panoilia E 

PROVIDER: S-EPMC4365273 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature